As Myriad seems to have thrown in the towel in its fight to protect patents covering its BRCA diagnostic tests, LSIPR asks whether the gene patent’s days are numbered in the US, and takes a look at its fortunes in other jurisdictions.
At the time of writing, genetic diagnostics company Myriad has settled all but one of its gene patent disputes with firms offering BRCA tests in the US.
The tests determine an individual’s chance of developing breast or ovarian cancer by analysing mutations on genes BRCA1 and BRCA2. Myriad holds a number of patents covering ways to isolate these genes, although some were invalidated by the US Supreme Court in a June 2013 decision.
However, gene patents remain in force in many jurisdictions around the world, including China, the EU, Japan, Russia and South Korea, where isolated DNA is considered patentable subject matter. Australia’s Full Federal Court last September upheld Myriad’s patents covering BRCA genes after a challenge by cancer survivor Yvonne D’Arcy.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
BRCA, Myriad, patent, gene patent
